glioma

A multi-region analysis of medulloblastoma and other tumor types highlighted the dramatic somatic alteration differences that can crop up within a single tumor.

Genetic mutations and tumor microenvironment largely account for differences between IDH-A and IDH-O gliomas, the researchers also said.

For the first time, the researchers also found a clear difference in risk factors for high-grade glioblastoma versus low-grade glioma.

Mutation and expression patterns in longitudinal, multifocal, and solitary tumor samples suggest glioblastoma follows a multiverse model of evolution.

In lower-grade glioma tumors lacking three known biomarkers, investigators identified TP53 and H3.3 histone mutations that appear to be linked to poor outcomes.

Short tandem repeat and expression data indicate that the U87MG cell line in the ATCC collection no longer represents the glioma from which it was established.

The companies will collaborate on clinical trials that utilize Tocagen's investigational treatment and RiboMed's prognostic assay technology.